Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?  Morgan Rouprêt, Per-Uno Malmstrom, Peter Black  European Urology Oncology  DOI: 10.1016/j.euo.2019.06.003 Copyright © 2019 The Authors Terms and Conditions

Fig. 1 Risk of recurrence or progression of Ta low-grade NMIBC. EORTC=European Organisation for Research and Treatment of Cancer; NMIBC=non-muscle-invasive bladder cancer. Adapted from Sylvester et al. [1]. European Urology Oncology DOI: (10.1016/j.euo.2019.06.003) Copyright © 2019 The Authors Terms and Conditions

Fig. 2 Multiphase, multiarm trial designs. BCG=bacillus Calmette-Guérin; EBRT=external beam radiotherapy; NMIBC=non-muscle-invasive bladder cancer; RP2D=recommended phase 2 dose. Adapted from Hahn [18]. European Urology Oncology DOI: (10.1016/j.euo.2019.06.003) Copyright © 2019 The Authors Terms and Conditions